Skip to the main content

Review article

Clinical Effects of Metoprolol Across the Cardiovascular Continuum.

Vjekoslav Tomulić orcid id orcid.org/0000-0002-3749-5559 ; University Hospital Centre Rijeka, Rijeka, Croatia
David Gobić ; University Hospital Centre Rijeka, Rijeka, Croatia
Milan Nikšić ; University Hospital Centre Rijeka, Rijeka, Croatia
Tomislav Jakljević ; University Hospital Centre Rijeka, Rijeka, Croatia
Zlatko Čubranić orcid id orcid.org/0000-0002-6989-5100 ; University Hospital Centre Rijeka, Rijeka, Croatia
Luka Zaputović orcid id orcid.org/0000-0001-9415-9618 ; University Hospital Centre Rijeka, Rijeka, Croatia


Full text: croatian pdf 103 Kb

page 44-48

downloads: 470

cite

Full text: english pdf 103 Kb

page 44-48

downloads: 456

cite


Abstract

Beta-adrenergetic receptor antagonists cause
positive effects across the whole cardiovascular continuum.
Compared to non-selective beta-blockers, cardioselective beta-1 blockers have an advantage in patients in whom we wish
to avoid beta-2 receptor blockade in the bronchi and peripheral blood vessels, in patients with bronchoobstructive and/or
peripheral arterial disease. A negative impact on blood glucose homeostasis and erectile function is to be avoided by selective application. Metoprolol has been internationally
known as widely applied and checked cardioselective betablocker for a long time. A series of clinical studies have clearly proved the therapeutic effect of metoprolol in the hypertension, acute and chronic types of coronary heart disease, postinfarction prophylaxis, heart arrhythmia and chronic heart failure syndrome. In all researches, metoprolol has showed good
tolerance and safety. If taking proper doses and managing patients properly, the side-effects are rare and reversible. Today,
metoprolol succinate is available in Croatia in the form with
sustained absorption and gradual plasma clearance with a
possibility of a one-day dosage which ensures stable concentration of the drug in the plasma and effects during a period of
24 hours. This is how a safer effect and better cooperation of
a patient required for the success of the treatment is achieved.

Keywords

cardiovascular diseases; beta-blockers; metoprolol succinate

Hrčak ID:

71484

URI

https://hrcak.srce.hr/71484

Publication date:

30.3.2011.

Article data in other languages: croatian

Visits: 2.258 *